2. Results
CM, headache
The characteristics of the 139 patients with CM enrolled in this study are summarized in In detail, 54 patients underwent BoNT-A injections in the trigeminal skin area and 36 patients in the occipital skin area. In contrast, 49 patients underwent placebo treatment in the trigeminal or occipital skin area. The reduction in monthly headache days between BoNT-A treatment and placebo was −13.2 versus −1.2 days, During follow-up, differences were found in HAMA and BDI-II scores compared with baseline in patients undergoing BoNT-A treatment; in the trigeminal group, BDI-II scores went from 12.65 ± 9.55 to 9.94 ± 9.93 (